share_log

HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $20

Benzinga ·  Dec 15, 2023 13:40

HC Wainwright & Co. analyst Ed Arce maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $18 to $20.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment